政策暖风频吹，国产创新药再迎催化，恒生医疗ETF(513060)午后涨超1%

Market Performance - The Hang Seng Healthcare Index increased by 0.76%, with notable gains from companies such as Baize Medical (+54.41%) and Brainstorm Aurora-B (+34.40%) [3] - The Hang Seng Healthcare ETF (513060) rose by 1.08%, with a recent price of 0.75 yuan, and has accumulated a 4.96% increase over the past two weeks, ranking in the top third among comparable funds [3] - The Hang Seng Hong Kong Stock Connect Innovative Drug Selection Index saw a 0.26% rise, with significant increases from companies like Yaojie Ankang-B (+42.96%) and MIRXES-B (+28.86%) [3] Liquidity and Trading Activity - The Hang Seng Healthcare ETF had a turnover rate of 21.64% and a trading volume of 1.586 billion yuan, indicating active market participation [3] - The Hong Kong Stock Connect Innovative Drug Selection ETF recorded a turnover rate of 27.79% and a trading volume of 105 million yuan, also reflecting a vibrant trading environment [4] Policy and Industry Developments - The State Council reviewed and approved the draft regulations for the management of clinical research and clinical application of biomedical new technologies, emphasizing the dual focus on innovation and safety [5] - The CSCO conference highlighted the rapid rise of China's clinical capabilities, with more Chinese experts becoming principal investigators in global studies, showcasing the international influence of China's innovative drug clinical research [5] Institutional Insights - The combination of supportive policies and international clinical integration is expected to catalyze the full industry chain development of domestic innovative drugs [6] - Companies with global clinical design and MRCT capabilities are likely to capture market share, despite potential review risks from stricter FDA policies [6] Related ETFs - The Hang Seng Healthcare ETF (513060) tracks the Hang Seng Healthcare Index, covering core assets in Hong Kong's healthcare sector [7] - The Hong Kong Stock Connect Innovative Drug Selection ETF (520690) closely follows the Hang Seng Hong Kong Stock Connect Innovative Drug Selection Index, focusing on leading innovative drug companies [8]